Biological response modifiers in human oncology and immunology.

Radio-adaptive doses effect on HT29 and MRC5 cell lines: comparison in hypo and hyper fractionation regime

Background: The exposure of cell lines to low-dose irradiation leads to changes at molecular level, which may induce adaptive response. We examined radio-adaptive doses effect on human colorectal adenocarcinoma cell line (HT29) and human fetal fibroblasts (MRC5) cell line followed by hyper and hypo fractionation regimes, with main purpose to decrease cell viability in HT29, and at the same time...

Natural Immunomodulators

Measurement of Affinity Constant of Anti-human IgG Monoclonal Antibodies by an ELISA-based Method

Background: The affinity of an antibody to its antigen is a crucial parameter in its biological activity and performance of an immunoassay such as ELISA. Affinity of most IgG specific MAbs are often determined by methods which require labeling of either antigen or antibody, and are sometimes difficult to control, do not always lead to the expected signal and often result in immunological modifi...

Biological and Clinicopathological Significance of Cripto-1 Expression in the Progression of Human ESCC

Background: Human Cripto-1, a member of the EGF-CFC family, is involved in embryonic development, embryonic stem cell maintenance, and tumor progression. It also participates in multiple cell signaling pathways including Wnt, Notch, and TGF-β. Remarkably, it is expressed in cancer stem cell (CSC) compartments, boosting tumor cell migration, invasion, and angiogenesis. Although Cripto-1 is ...

KIR2DS3 is Associated with Protection against Acute Myeloid Leukemia

Background: Interaction between killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules is important for regulation of natural killer (NK) cell function. Objective: The aim of this study was to investigate the impact of compound KIR-HLA genotype on susceptibility to acute leukemia. Methods: Cohorts of Iranian patients with acute myeloid leukemia (AML;...